Comparative Pharmacology
Head-to-head clinical analysis: HIPPUTOPE versus SELENOMETHIONINE SE 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPUTOPE versus SELENOMETHIONINE SE 75.
HIPPUTOPE vs SELENOMETHIONINE SE 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPUTOPE is a diagnostic agent used to assess renal function. It is a radiolabeled compound that undergoes glomerular filtration and tubular secretion, allowing measurement of renal plasma flow and tubular function via imaging.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
100-300 microcuries (3.7-11.1 MBq) intravenous, single dose for renal imaging.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours; prolonged to 6–12 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Primarily renal excretion (approximately 90% as unchanged drug via glomerular filtration), with minor biliary/fecal elimination (<10%).
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical